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Abstract: Hydroxy acids (HAs) represent a class of compounds which have been widely 
used in a number of cosmetic and therapeutic formulations in order to achieve a variety of 
beneficial effects for the skin. We review and discuss the most frequently used classes of these 
compounds, such as α-hydroxy acids, β-hydroxy acids, polyhydroxy acids, and bionic acids, 
and describe their applications as cosmetic and therapeutic agents. Special emphasis is devoted 
to the safety evaluation of these formulations, in particular on the effects of their prolonged 
use on sun-exposed skin. Furthermore, we summarize the very limited number of studies 
dealing with the modifications evoked by topical application of products containing HAs on 
photocarcinogenesis. In spite of the large number of reports on the cosmetic and clinical effects 
of HAs, their biological mechanism(s) of action still require more clarification. Some of these 
mechanisms are discussed in this article along with important findings on the effect of HAs 
on melanogenesis and on tanning. We also emphasize the important contribution of cosmetic 
vehicles in these types of studies. Thus, HAs play an important role in cosmetic formulations, 
as well as in many dermatologic applications, such as in treating photoaging, acne, ichthyosis, 
rosacea, pigmentation disorders, and psoriasis.
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Introduction
Formulations containing hydroxy acids (HAs) have been used in clinical practice 
for decades to treat a variety of skin conditions. The most prominent representatives 
in this class of compounds are glycolic acid, lactic acid, and salicylic acid (SA) 
 ( Figure 1). HA have transformed skin care since their introduction to dermatology.1 
They have been used, typically in concentrations ranging from 2% to 70%, to treat 
acne, ichthyosis, keratoses, warts, psoriasis, photoaged skin, and other disorders.2 
In the last three decades, α-hydroxy acids (αHAs) have been widely incorporated 
into a variety of cosmetic products for daily use over long periods of time.3 Currently, 
glycolic acid, lactic acid, and SA are commonly used in cosmetics. One of the most 
cited beneficial effects of HAs is the reported improvement of photoaged skin. These 
improvements have been measured as decreases in roughness, discoloration, solar 
keratoses, and overall pigmentation and also as increased density of collagen and 
improved quality of elastic fibers.4 The antiaging effects of HA have become a promi-
nent factor in cosmetic dermatology, leading to the proliferation of HA-containing 
cosmetic products and skin care systems.4 More recent research in this field led to 
the discovery of polyhydroxy acids (PHAs) and aldobionic acids (BAs) (Figure 1), 
which are presently widely used in cosmetic and dermatologic applications.5 Many Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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  preparations that contain HAs are both exfoliants and 
  moisturizers. In low concentrations (4%–10%), they are 
ubiquitous components of nonprescription creams and 
lotions that are promoted as being effective for ameliorating 
skin aging. In high concentrations (.20%), these prepara-
tions are used as chemical ‘peels’ to treat calluses, keratoses, 
acne, psoriasis, and photoaging.
This review is intended to provide a summary of the 
most frequently used classes of HAs, to describe their appli-
cations as cosmetic and therapeutic agents, and to discuss 
their biologic mechanisms of action. We initially discuss the 
types/classes of HAs, then consider their safety evaluation, 
implications to photocarcinogenesis, mechanisms of their 
biological actions, and their effects on pigmentation.
Types/classes of HAs
αHAs
αHAs are carboxylic acids with one hydroxyl group atta-
ched to the α-position of the carboxyl group. The simplest 
  representative of αHA is glycolic acid (chemical name, 
hydroxyacetic acid), which was the first of this class of 
compounds to be introduced into skin care products.3 Lactic 
acid, with optimal biologic activity in its l-form, is also used 
in various topical formulations to exfoliate the skin and also 
to provide antiaging properties.6
PHAs
A new generation of αHAs, called PHAs and polyhydroxy 
bionic acids (PHBAs), provide effects similar to αHAs but 
with less irritation responses. PHAs, such as lactobionic acid 
(Figure 1), are carboxylic acids with two or more hydroxyl 
groups attached to carbon atoms or an alicyclic chain. It is 
essential that at least one hydroxyl group be attached to 
the α-position. Attaching a sugar molecule to the PHA 
structure results in a polysaccharide known as bionic acid. 
Multiple skin benefits have been proven for the PHAs and 
PHBAs, making them ideal ingredients for use in dermato-
logic and cosmetic procedures.5
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β-Hydroxy acids
β-Hydroxy acids (βHAs) are carboxylic acids having one 
hydroxyl group attached to the β-position of the carboxyl group. 
The most common βHA is β-hydroxybutanoic acid. A lipid 
soluble βHA is tropic acid (2-phenyl-3-hydroxypropanoic 
acid) (Figure 1). Some βHAs are also considered αHAs 
as they contain a hydroxyl group in the α-position to one 
carboxyl group and in the β-position to the other carboxyl 
group. Malic acid and citric acid are prominent representa-
tives in this category (Figure 1). Citric acid is widely used 
in topical formulations as an antioxidant, and its antiaging 
benefits are well established.7
SA
In the cosmetic and dermatologic literature, SA is often 
described as a βHA, but that classification is incorrect.8 
In SA, both the hydroxyl and the carboxyl groups are directly 
attached to an aromatic benzene ring and both exhibit acidic 
properties. In contrast, the hydroxy groups in αHAs, βHAs, 
and PHAs are neutral under the conditions used in clinical 
and cosmetic settings. On the basis of knowledge to date, 
SA does not function physiologically or therapeutically as 
a βHA. SA is used in cosmetic formulations for a variety of 
applications, more specifically, it is fat soluble, which makes 
it useful in subjects with oily skin.
Safety evaluation of HAs
Questions have been raised about the safety of prolonged use 
of HA-containing products on sun-exposed skin. A number of 
clinical studies have reported that topical application of gly-
colic acid can increase sensitivity of the skin to solar-simulated 
radiation (SSR).9 Most of these studies used vehicles which 
differ significantly from those used in cosmetic products. 
Furthermore, only a single cutaneous biomarker for UV-
induced damage was usually measured. In the few cases in 
which multiple endpoints were used, they were not evaluated 
in the same subject.10 In a previous study using 16 subjects, 
we reported that 10% glycolic acid, applied 6 days/week for 4 
weeks, enhanced the sensitivity to UVB radiation, measured as 
increased sunburn cell formation, and also lowered the minimal 
erythemal dose (MED).10 In another cohort group (n = 13), 
levels of cyclobutane pyrimidine dimers were elevated in 
αHA-treated skin, but not to a statistically significant level. 
We also found that the enhanced photosensitivity was reversed 
within a week of terminating the treatments. Another of our 
collaborative studies was designed to generate new data on 
the effects of topically applied glycolic acid and SA on the 
sensitivity of human skin to SSR.9 A total of 14 subjects with 
skin types II to III were involved in that study. Biomarkers 
measured were erythema, cyclobutane pyrimidine dimers, 
and sunburn cells (apoptotic keratinocytes). The protocol 
was designed to allow us to measure all of the above biomark-
ers in each subject, with the vehicle-treated skin of each subject 
serving as his/her own control. We found that glycolic acid 
(10%) increased the SSR sensitivity of human skin, whereas 
SA (2%) did not. The photosensitizing effects of glycolic acid 
were small, but they may be an important factor for public 
health, considering that HA-containing products are being 
used by a large segment of the population for many years and 
in many cases over a lifetime.
In 1998, the Cosmetic Ingredient Review (CIR) Expert 
Panel evaluated the available evidence and concluded that αHA 
ingredients are not mutagenic or carcinogenic, are not reproduc-
tive or developmental toxins, and are not skin sensitizers.11 To 
reduce the risk of skin irritation, the CIR Panel recommended 
limitations on the concentration of αHAs (,10%) and the pH 
(at or above 3.5) of cosmetic products containing αHAs. In 
addition, the CIR Panel recommended that αHA-containing 
products should be formulated to avoid enhancing sun sensi-
tivity and that consumers should be advised to use daily sun 
protection.11 SA is added to cosmetic products at concentrations 
,3%.12 The CIR Panel similarly recommended that effects on 
skin sensitivity to sunlight be considered in the formulation and 
use of products containing SA and salicylates.12
Photocarcinogenesis
The importance of solar UVR exposure in the etiology of 
cutaneous tumorigenesis has long been firmly established. 
The nature and magnitude of the modifications evoked by 
topical application of various cosmetic/therapeutic products 
are much less understood. An extensive project, sponsored by 
the National Toxicology Program, of the photocarcinogenic 
potential of HAs in SKH-1 mice was recently completed.13 
That study was designed to test the hypothesis that topical 
application of creams containing glycolic acid (4% or 10%; 
pH 3.5) or SA (2% or 4%; pH 3.5) on mice could enhance 
the rate of skin cancers induced by SSR. In order to test this 
hypothesis, mice were treated 5 days/week with each cream, 
followed by exposure to SSR. This treatment was contin-
ued for 40 weeks, followed by 12 weeks of no additional 
treatment prior to sacrifice of the animals. Tumors induced 
under the described experimental conditions in mice were 
squamous cell papillomas, carcinomas in situ, and squamous 
cell carcinomas. Taking into consideration the survival data, 
time to tumor data, and the pathology results, glycolic acid 
did not alter the photocarcinogenesis induced by SSR, while Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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SA at 4% showed a photoprotective activity, reducing the 
carcinogenicity of SSR.
The role of the vehicle control cream was also inves-
tigated in that study. Surprisingly, a SSR dose-dependent 
increase in the formation of skin neoplasms was observed in 
mice treated with the control cream compared with mice not 
treated with the cream. These results indicate that the con-
trol cream enhanced the photocarcinogenesis of SSR in the 
SKH-1 mice under these test conditions. They further indicate 
that the proper control groups for statistical comparison of 
the effects of glycolic acid or SA are mice that received the 
control cream, and not the mice untreated with a cream.13
In addition to the described photocarcinogenesis study, 
the same investigators examined the acute proliferative 
effects of glycolic acid (10%; pH 3.5–4.0) and SA (4% or 
10%; pH 3.5–4.0) on cell proliferation in the epidermis of 
SKH-1 female mice, using BrdU incorporation as a marker 
of epidermal proliferation.14 They found a dose-dependent 
increase in epidermal proliferation in mice treated with 
either glycolic or SA. A similar response was observed in 
the epidermal thickness of mice treated with SA, but not 
with glycolic acid. Their study demonstrates that topical 
administration of glycolic acid or SA can affect cellular 
proliferation in mouse epidermis. In a second study, the 
same authors described the effect of the corresponding 
formulations of glycolic acid and SA on the edemal response 
to SSR in female SKH-1 mice.15 They found that the use of 
creams containing glycolic or SA for up to 6 weeks does not 
increase the susceptibility to an edemal response caused by 
exposure to SSR. The effects of the long-term use of such 
creams in combination with exposure to SSR are yet to be 
established. It is noteworthy that the vehicle and test materials 
used in the above described chronic and acute studies in mice 
had the same composition and origin as those used in our 
clinical study.9 Furthermore, the spectral distribution of the 
SSR sources was the same in all these studies. This allows 
a comparison between results on HA-induced changes in 
acute responses to SSR in humans and their corresponding 
responses in an animal model.
In 2001, Hong et al published a study on the photocar-
cinogenic potential of topically applied glycolic acid in 
SKH-1 mice. They found that glycolic acid had an inhibitory 
effect against UV-induced skin tumor development in this 
system.16 The protective effect of glycolic acid was a 20% 
reduction of skin tumor incidence, a 55% reduction in tumor 
multiplicity (average number of tumors/mouse), and a 47% 
decrease in the number of large tumors (.2 mm). Glycolic 
acid also delayed the first appearance of tumor formation 
by about 3 weeks. There are, however, some important 
differences between the experimental designs described by 
Hong et al compared to the protocol applied in the National 
Toxicology Program study, which greatly limit comparison 
of the results from the two studies. In the study of Hong et al 
glycolic acid was dissolved in polyethylene glycol and was 
applied at a large dose of 8 mg/cm2 (the authors called it a 
therapeutic dose) on the skin. The UV irradiation was carried 
out with a UV lamp source, not with SSR. Furthermore, the 
omission of a vehicle control group in the study of Hong et al 
raises additional concern.
The effects of the topical control cream have been 
described by several other investigators. It has been known 
for some time now that topically applied formulations such 
as emollients and moisturizers may influence the optical 
properties of the skin and therefore may influence the opti-
cal effectiveness of UV exposures. Moisturizing creams and 
ointments used for the prevention and treatment of dry skin 
are generally tested for safety by determining their irritant 
and sensitizing (immunological response) activities. These 
preparations are generally not tested for their carcinogenic 
or cocarcinogenic properties. A significant contribution to 
this field was recently published by Lu et al.17 They devel-
oped an animal model (SKH-1 mice) that mimics sunlight-
induced skin cancers in humans who receive heavy exposure 
to sunlight early in life, but develop skin cancers later in 
life in the absence of subsequent heavy sunlight exposure. 
To accomplish this, SKH-1 mice were treated twice weekly 
with UVB for 3 months and after that they were no longer 
exposed to UVB. These mice do not have tumors, but they 
do have a high risk for developing skin tumors over the next 
several months even in the absence of further UVB irradia-
tion (high-risk mice). The authors tested four commercially 
available and widely used moisturizing creams and found that 
all of them had tumorigenic activity when applied topically 
to high-risk mice. Histological characterization of the tumors 
was not done in their study. Prior to the report by Lu et al 
little attention was paid to the possibility of a post-UV effect 
by these seemingly innocuous formulations. The study by 
Lu et al raises the question of whether these agents belong to a 
list of more active compounds analogous to tumor promoters 
in two-stage carcinogenesis, in which UVB is the initiator.18 
It has to be emphasized that this study was performed in 
mice, and therefore, its significance for humans remains 
unproven. It should be noted that the stratum corneum plays 
an important role in photoprotection, and since many of the 
HAs have exfoliative effects, that might at least in part play 
a role in changes in photoprotection.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Mechanism of biological actions  
of HAs
Although there are many reports about the cosmetic and 
clinical effects of HAs, their biological mechanism(s) of 
action still needs to be clarified. Several key studies relevant 
to this important issue will be discussed here.
αHAs
Based on analysis of available experimental and clinical 
data, Wang proposed a mechanism of action for αHAs topi-
cally applied to the skin.19 That analysis was based on data 
regarding the chelation properties of αHAs20 and the fact that 
calcium ions are known to play a crucial role in cutaneous 
cellular adhesions.21 Wang proposed a theory that αHAs 
reduce the Ca ion concentration in the epidermis and remove 
Ca ions from the cell adhesions by chelation. This process 
would cause a loss of Ca ions from the cadherins of the 
desmosomes and adherens junctions. When Ca is decreased, 
cellular adhesions are disrupted and exfoliation takes place. 
Wang further proposed that the decrease of Ca ions in the 
epidermis also tends to promote cell growth and to retard cell 
differentiation, and therefore caution should be taken regard-
ing excessive and chronic use of these compounds.
Okano et al conducted a study that investigated the effects 
of glycolic acid on the dermal matrix metabolism of kera-
tinocytes and fibroblasts using in vitro and ex vivo (human 
skin biopsies) systems.22 That study showed that glycolic 
acid not only directly accelerates collagen synthesis by 
fibroblasts, but that it also modulates matrix degradation and 
collagen synthesis through keratinocyte-released cytokines. 
Their experiments confirmed that IL-1a is one of the primary 
mediators regulating matrix degradation that are released 
from keratinocytes after glycolic acid treatment. On the 
basis of their findings, the authors suggest that glycolic acid 
contributes to the recovery of photodamaged skin through 
various pathways, depending on the skin cell type.
In an additional effort to study the mechanism of improve-
ment of photoaged skin by HA, Bernstein et al investigated the 
effects of glycolic acid on epidermal and dermal hyaluronic acid 
production and on the induction of collagen gene expression.23 
They compared collagen gene expression from skin biopsy 
specimens and hyaluronic acid immunohistochemical staining 
from glycolic acid- and vehicle-treated skin. Sun-damaged 
forearm skin was treated with 20% glycolic acid lotion or a 
lotion vehicle control (oil in water; pH 3.9) twice a day for 
3 months. The authors found that this protocol increased epi-
dermal thickness, epidermal and dermal levels of hyaluronic 
acid, and collagen gene expression. Even small increases in 
the content of cutaneous hyaluronic acid may result in large 
changes in epidermal and dermal hydration, affecting skin 
appearance, texture, and function. With the growing concern 
regarding the photosensitivity aspects of HAs, this study docu-
ments some of the beneficial effects of glycolic acid.
Another proposed mechanism for the biological actions 
of HA was described by Rendl et al.6 They investigated the 
effects of creams containing lactic acid on the secretion of 
cytokines by keratinocytes in human reconstructed epidermis.6 
They found that topically applied creams containing lactic 
acid (1.5%, 3%, or 5%) led to a concentration-dependent 
increase in apoptotic cells compared to the vehicle control. In 
addition, they found an increase in the secretion of vascular 
endothelial growth factor (VEGF) over the vehicle control 
after treatment with 1.5% or 3% lactic acid. No significant 
increase in VEGF secretion was detected following treatment 
with 5% lactic acid. In contrast to this finding, the secretion 
of angiogenin was decreased by lactic acid in a concentration-
dependent manner. No significant changes in IL-8 secretion 
were elicited by lactic acid at any of the concentrations tested. 
The authors concluded that topical application of lactic acid 
modulates the secretion of cytokines by keratinocytes and that 
this regulation might represent a mechanism contributing to 
their therapeutic effects such as photoaging.6
SA and derivatives
SA is widely used in cosmetic formulations (concentration 
2%–4%) and also therapeutically as a keratolytic (peeling) 
agent to treat skin conditions, such as calluses, keratoses, 
acne, and photoaging. It is applied in various concentrations, 
vehicles, and pHs, depending on the numbers of lesions. 
Several experimental and clinical studies have found that 
topically applied SA is photoprotective. It has been reported 
that repeated topical application of SA or sodium salicylate 
protects SKH-1 mice from skin carcinogenesis induced by 
UV radiation.24 SA, applied to human skin shortly before 
exposure to UV radiation, was reported to decrease the ery-
themal response.25 One clinical investigation reported that 
SA (in a non-UV absorbing vehicle) had a pronounced filter 
effect when applied prior to UVB exposure.26 SA added after 
UVB exposure had no measurable effect. The authors, there-
fore, discounted the contribution of the anti-inflammatory 
property of SA under the conditions of their experiment. In 
addition, Kristensen and Kristensen also performed a double-
blind clinical trial on patients with plaque psoriasis,26 and 
most subjects (73%) cleared less on the side pretreated with 
SA. The authors concluded that SA provides photoprotection 
of sufficient degree to warrant advising patients not to use SA Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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concomitantly with UVB therapy. More recently, Birgin et al 
reported their results on the effect of topical petrolatum and 
SA (20%) upon skin photoreaction to UVA.27 They concluded 
that the application of SA in petrolatum before PUVA therapy 
is not recommended because of its UVA-blocking effect.
The antibacterial action of SA has been known for many 
decades. One recent study indicates that SA acts at the level 
of transcription to downregulate the production of fibrinogen, 
fibronectin, and α-hemolysin virulence factors necessary for 
bacterial replication in host tissues. Whether SA affects bac-
terial growth in acne was not reported in this study.28 A C-8 
derivative of SA known as β-lipohydroxy acid (βLHA), 
developed in the late 1980s, has been proposed as an exfoliant 
and as a treatment of photoaged skin and acne.29 βLHA has an 
eight-carbon fatty chain linked to the benzene ring making it 
more lipophilic than SA. This may account for its slower skin 
penetration. βLHA was shown to have a good safety profile 
with lower irritation when compared to glycolic acid.30 βLHA 
also showed activity in reducing melanosome clustering and 
epidermal pigmentation. Contrary to αHAs, βLHA increased 
the skin’s resistance to UV-induced damage.30,31 βLHA has 
antibacterial effects, which are ideal for the treatment of acne.30 
Recently, Saint-Leger et al described in detail the properties of 
βLHA, its cosmetic and clinical applications, and its biologic 
mechanism of action.32 The authors specifically discussed 
βLHA’s antimicrobial, anti-inflammatory, antifungal, and anti-
comedogenic properties. In summary, SA and its derivatives 
represent a rare case of a drug being used for over a century 
with no tendency to be replaced in the near future.
PHAs
As mentioned in the Introduction, PHAs and PHBAs represent 
the next generation of αHAs for use in cosmetic and dermato-
logic skin care.5 PHAs are αHAs containing multiple hydroxyl 
groups, while PHBAs are PHAs with an additional sugar 
molecule attached to the PHA structure. PHAs and PHBAs 
provide clinically proven antiaging and skin-smoothing effects 
that are comparable to αHAs, while offering several thera-
peutic advantages. In addition, these molecules function as 
humectants and moisturizers, as well as providing antioxidant 
chelation effects.5 The most popular PHA marketed today is 
gluconolactone (Figure 1). Bernstein et al conducted a study 
both in vitro and in a clinical setting, which demonstrated that 
gluconolactone can protect against the detrimental effects of 
UV radiation.33 They exposed fibroblast cultures obtained 
from the skin of transgenic mice to UVB, in the presence or 
absence of gluconolactone solutions. They demonstrated a 
dose-dependent protection of gluconolactone compared to 
the controls. As the UV absorption of gluconolactone is low, 
they concluded that its protective effect must be due to other 
mechanisms, such as its ability to function as a chelating agent 
and potency in scavenging free radicals. In the clinical part of 
that study, the authors treated 11 volunteers, with skin types 
I–III, with 8% glycolic acid lotion, with 8% gluconolactone 
lotion (lotion not specified), or with no treatment for 1 month 
(the effect of the lotion itself was not reported). After the last 
topical application of lotions, each site was irradiated with 
a dose of 1.5 MEDs from a SSR source. The glycolic acid-
treated skin demonstrated a significant increase in sunburn 
cells, whereas the gluconolactone-treated site did not.33
effects of HAs on pigmentation
An additional, much less explored property of HAs is their 
effect on pigmentation. αHAs, such as glycolic acid and 
lactic acid, have been reported to be effective in treating 
pigmentary lesions including melasma, solar lentigines, 
and postinflammatory hyperpigmentation. The proposed 
mechanism of this effect was believed to be due to epidermal 
remodeling and accelerated desquamation, which should 
result in quicker pigment dispersion. In 2003, Usuki et al 
published an in vitro study which showed that glycolic acid 
and lactic acid (300–500 µg/mL) suppressed melanin forma-
tion by directly inhibiting tyrosinase activity in human and 
mouse melanoma cells.34 They also reported that this effect 
was independent of the acidic nature of the HAs involved. 
Using their in vitro system, the authors conclude that glycolic 
acid and lactic acid might work not only by accelerating the 
epidermal turnover, but also by directly inhibiting   melanin 
formation in melanocytes. If confirmed, their findings should 
have important clinical significance. The effect of topically 
applied HAs on tanning has been less examined. Tsai et al 
investigated the effects of glycolic acid on light-induced 
skin pigmentation in 6 Asian and in 6 Caucasian subjects.35 
  Subjects received UVA and UVB irradiations to both sides of 
the lower back and on the contralateral extensor forearms once 
daily for 7 days and then twice daily for 7 weeks. A placebo 
gel was applied to the opposite sides. They found increased 
UVB-induced tanning on the forearm and the lower back in 
both races in areas pretreated with glycolic acid. UVA caused 
increased tanning only on the exterior forearms in Asian 
  subjects. The authors proposed that this small panel of subjects 
should be enlarged in future studies. To our knowledge, all 
these clinical studies were performed in subjects having skin 
types I–III. In order to address safety issues of populations 
with darker skin types, corresponding investigations with 
cohorts having skin types IV–VI are needed.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Cosmeceuticals
Cosmeceuticals are cosmetic products that contain both 
cosmetic and biologically active ingredients purporting to 
have medical and/or drug-like benefits. The term is widely 
used not only in cosmetic advertising, but also in periodi-
cals, monographs, and promotional materials. However, the 
Federal Food, Drug and Cosmetic Act does not recognize 
any such category as ‘cosmeceuticals’. A product can be 
a cosmetic, a drug, or a combination of both, but the term 
‘cosmeceuticals’ has no meaning under the law (see http://
www.fda.gov/Cosmetics/ProductandIngredientSafety/
PrductInformation/ucm127064.htm).
Conclusion
HAs have transformed approaches to skin care and have 
enjoyed huge success since their introduction to cosmetic 
and therapeutic dermatology about four decades ago.4 In 
spite of a large number of studies on HAs that have accumu-
lated over this period, there is still an inadequate amount of 
information to assess the safety of topical application of these 
products. In many cases, it is difficult to compare the results 
of individual studies as they are performed under various 
conditions. The concentrations and pHs of the active ingre-
dients, the timing of the application of the products, and most 
importantly, the composition of the control vehicle show 
significant variations. In studies involving UV-exposures, 
the light sources also differed significantly and were often 
not adequately defined. On the other hand, from all those 
studies, we have learned that topically applied HAs are 
capable of interacting with many basic biological processes 
that occur in mammalian skin (summarized in Table 1). They 
can affect and modify the processes of cell proliferation, 
cytokine excretion, and induction of apoptosis and can act 
as antioxidant/chelators, influence the skin barrier function, 
and act as moisturizers. Some investigators, therefore, still 
recommend that caution should be taken when using these 
products, in particular with their chronic use.
For further reading, the authors highly recommend the 
important contributions by van Scott et al36 and Green et al37 
as well as a recently published monograph edited by Zoe 
Draelos.38 They contain a treasure of information on the 
subject as well as provide ideas for planning future studies 
on the safety of HAs.
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Table 1 Applications of hydroxy acids
Types/classes of HAs Safety evaluation Photocarcinogenesis Mechanism of biological action
αHAs Not mutagenic or carcinogenic,  
not reproductive or  
developmental toxins,  
not skin sensitizers11
No alteration of  
photocarcinogenesis  
induced by SSR13
Reduced Ca ion concentration in the epidermis 
disrupts cellular adhesions by removing Ca ions 
from the cell adhesions by chelation allowing for 
exfoliation; promoting cell growth and retarding 
cell differentiation19
Glycolic acid Increased SSR sensitivity in  
human skin9,10 
Increased epidermal  
thickness, epidermal and dermal  
levels of hyaluronic acid, and  
collagen gene expression23
Increased epidermal  
proliferation in mice14
Acceleration of collagen synthesis by fibroblasts 
and also modulation of matrix degradation and 
collagen synthesis through keratinocyte-released 
cytokines22 
Accelerated epidermal turnover and inhibition 
of melanin formation in melanocytes by directly 
inhibiting tyrosinase activity34 
Pretreatment increased Uv-induced 
pigmentation35
PHA Photoprotective  
(gluconolactone)33
Function as a chelating agent and exhibits 
potency in scavenging free radicals33
βHA – – –
SA enhances percutaneous penetration,   
not a photosensitizer, not  
phototoxic, no change in SSR  
sensitivity in human skin9 
Uv effects on skin sensitivity  
should be considered due to its  
keratolytic action on human skin12
Photoprotective, reducing the   
carcinogenicity of SSR13,24 
Increased epidermal  
proliferation and thickness  
in mice14
Acts at the level of transcription to 
downregulate the production of fibrinogen, 
fibronectin, and α-hemolysin virulence factors 
necessary for bacterial replication  
in host tissues28Clinical, Cosmetic and Investigational Dermatology
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